Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod plus tofacitinib in rheumatoid arthritis with inadequate response to conventional or biologic DMARDs
ChiCTR2500103373Phase 4Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iguratimod and tofacitinib in rheumatoid arthritis (RA), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: ACR20 achievement rate, ACR50 achievement rate and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
iguratimodtofacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2500103373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103373.